Evidence map›Paper›PMID 39792837›Full record

ArticlePloS one2025

Effects of recombinant human growth hormone in severe neurosurgical patients: A single center, retrospective study.

Xixian Liao, Haorun Huang, Binghui Qiu, Jiaping Chen, An Zhang, Haoxin Liang, Chuanping Huang, Fen Mei, Jian Mao, Fan Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xixian LiaoDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Haorun HuangDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Binghui QiuDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jiaping ChenDepartment of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
An ZhangDepartment of Laboratory for Precision Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Haoxin LiangSecond Clinical Medicine School, Southern Medical University, Guangzhou, Guangdong, China.
Chuanping HuangDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Fen MeiDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jian MaoDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Fan LiuDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Ming JinDepartment of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Xiaojie PengDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Haidie MaFirst Clinical Medicine School, Southern Medical University, Guangzhou, Guangdong, China.
Wenjie DingFirst Clinical Medicine School, Southern Medical University, Guangzhou, Guangdong, China.
Songtao QiDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID 0000-0001-7600-9528
Yun BaoDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore the effects of recombinant human growth hormone (r-hGH) on inflammatory mediators, immune cells and prognosis in severe neurosurgical patients.

methodsFrom August 2020 to June 2021, a total of 236 patients who admitted to the neurosurgical intensive care unit (NSICU) were retrospectively analyzed. The patients were divided into GH group (97 cases) and nGH group (139 cases) according to whether they received r-hGH treatment. Parameters including CD4+ T cell counts, inflammatory mediators and prognosis were recorded and assessed.

resultsThe results showed that the cure time of pneumonia and intracranial infection in GH group patients was significantly shorter than in the nGH group (24.25 ± 4.89 days and 21.33 ± 1.53 days versus 29.13 ± 7.43 days and 25.17 ± 2.32 days, respectively). However, there was no significant difference in GOS scores between two groups (31.96% ≤ 3 and 68.04% > 3 vs 39.57% ≤ 3 and 60.43% > 3) (P = 0.232). Furthermore, the number of CD4+ T cells and CD8+ T cells in the GH group showed a significant upward trend. Last but not least, significant differences were also observed in IL-6 and IL-10 levels between two groups at days 1, 3, and 7.

conclusionThe application of r-hGH in severe neurosurgical patients was effective in increasing the number of CD4+ T cells, down-regulating inflammatory mediators, shortening the cure time of pneumonia, intracranial infections and urinary tract infections, and improving patients' prognosis.

Indexed as

Human Growth HormoneRecombinant ProteinsAdultAgedCD4-Positive T-LymphocytesFemaleHumansMaleMiddle AgedNeurosurgical ProceduresPneumoniaPrognosisRetrospective StudiesHuman Growth HormoneRecombinant Proteins

Identifiers

PMID39792837
PMCPMC11723630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.